Jamshedpur Reporter

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Facioscapulohumeral Muscular Dystrophy (FSHD) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Facioscapulohumeral Muscular Dystrophy, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Facioscapulohumeral Muscular Dystrophy Market

• The market size for Facioscapulohumeral Muscular Dystrophy (FSHD) in the leading markets is expected to grow significantly by 2036.

• The 7MM FSHD market is projected to increase substantially during the forecast period 2026–2036, driven by the anticipated launch of emerging disease-modifying therapies and increasing diagnosis rates.

• In 2025, the United States accounted for approximately 45% of the total diagnosed FSHD cases across the 7MM, with patient numbers expected to increase through 2036.

• In 2025, there were nearly 16,000 cases of FSHD1 and approximately 800 cases of FSHD2 in the United States.

• According to McNiff et al. (2023), approximately 95% of patients are diagnosed with FSHD Type 1, while the remaining cases are classified as FSHD Type 2.

• According to Sanson et al. (2022), the prevalence of FSHD is estimated to be approximately 1 in 8,000 to 1 in 15,000 in the United States and around 1 in 20,000 in both Italy and the United Kingdom.

• According to the FSHD Society, FSHD1 accounts for nearly 95% of all cases, while FSHD2 represents the remaining 5% of patients.

• According to the National Organization for Rare Disorders (NORD) (2020), FSHD affects males and females in relatively equal numbers, with an estimated prevalence of 4–10 cases per 100,000 individuals.

• Leading FSHD companies, including Novartis, Roche, Chugai Pharmaceutical, Epicrispr Biotechnologies, Modalis Therapeutics, Restem, and others, are actively developing innovative therapies expected to transform the FSHD treatment landscape over the coming years.

• Promising Facioscapulohumeral Muscular Dystrophy therapies in clinical development include Delpacibart braxlosiran (del-brax), GYM329/RO7204239/RG6237, EPI-321, MDL-103, Restem-L, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market

Key Factors Driving the Facioscapulohumeral Muscular Dystrophy Market

Increasing Awareness and Improved Genetic Diagnosis

Growing awareness among healthcare professionals, improved availability of genetic testing, and enhanced understanding of the molecular basis of FSHD are facilitating earlier diagnosis and appropriate disease management. Increasing diagnosis rates are expected to expand the treated patient population and support market growth.

Rapid Advancement of Gene-targeted Therapies

The FSHD therapeutic pipeline has expanded considerably with multiple companies developing innovative therapies designed to suppress DUX4 expression, inhibit myostatin, and improve muscle strength and function. These disease-modifying approaches have the potential to significantly alter the treatment paradigm for FSHD.

Growing Investment in Rare Neuromuscular Disorders

Increasing investment from biotechnology and pharmaceutical companies, coupled with orphan drug incentives, strategic acquisitions, and advances in RNA-targeting and gene-editing technologies, is accelerating clinical development and creating substantial growth opportunities within the FSHD market.

Facioscapulohumeral Muscular Dystrophy Competitive Landscape

The current Facioscapulohumeral Muscular Dystrophy treatment landscape remains limited to supportive care, rehabilitation, pain management, and surgical interventions, as no disease-modifying therapy has yet received regulatory approval for FSHD. Current management primarily focuses on improving mobility, preserving muscle function, reducing complications, and enhancing patients’ quality of life through physical therapy, exercise programs, scapular fixation surgery, and symptomatic pharmacological treatment.

The competitive landscape is evolving rapidly with several promising therapies targeting the underlying genetic mechanisms of FSHD. Delpacibart braxlosiran (del-brax) is designed to suppress abnormal DUX4 expression through RNA-targeted therapy, while GYM329/RO7204239/RG6237 targets myostatin inhibition to improve muscle strength. Additional investigational therapies, including EPI-321, MDL-103, and Restem-L, are advancing through clinical development and represent significant opportunities to address the substantial unmet medical needs associated with this progressive neuromuscular disorder.

Discover more about therapies set to grab major Facioscapulohumeral Muscular Dystrophy market share @ Facioscapulohumeral Muscular Dystrophy Treatment Landscape

Recent Developments in the Facioscapulohumeral Muscular Dystrophy Market

• In January 2026, Novartis completed its acquisition of Avidity Biosciences, strengthening its neuromuscular disease pipeline and gaining access to Delpacibart braxlosiran (del-brax), a promising RNA-targeted therapy for Facioscapulohumeral Muscular Dystrophy.

• In December 2025, Restem announced that the first patient had been dosed in the Phase I/IIa clinical study evaluating Restem-L in patients with Facioscapulohumeral Muscular Dystrophy. The clinical trial is being supported through a partnership with SOLVE FSHD.

• In August 2025, Epicrispr Biotechnologies announced dosing of the first patient in its global first-in-human Phase I/II clinical trial evaluating EPI-321, an investigational gene-modulating therapy designed to silence DUX4 expression through epigenetic modulation.

• In October 2025, Avidity Biosciences reported that the Phase III FORTITUDE-3 trial evaluating Delpacibart braxlosiran (del-brax) is underway, with topline biomarker data expected in Q2 2026 and global regulatory submissions anticipated in 2028.

• In September 2024, Fulcrum Therapeutics announced that the Phase III REACH trial evaluating losmapimod failed to meet its primary endpoint, leading the company to discontinue further development of the investigational therapy for FSHD.

What is Facioscapulohumeral Muscular Dystrophy?

Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most common inherited adult-onset muscular dystrophies, characterized by progressive weakness and wasting of the facial, shoulder-girdle, and upper-arm muscles. As the disease progresses, weakness may extend to the abdominal, pelvic-girdle, and lower-limb muscles, resulting in impaired mobility and reduced quality of life.

FSHD is primarily classified into FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2). The disorder is caused by abnormal activation of the DUX4 gene, resulting from genetic alterations involving the D4Z4 repeat region on chromosome 4 or other associated genetic mechanisms. Symptoms commonly begin during the first or second decade of life, although disease onset and severity vary considerably among individuals. Diagnosis is based on clinical evaluation and confirmatory genetic testing. Currently, there is no approved disease-modifying therapy for FSHD, and treatment primarily focuses on rehabilitation, physical therapy, pain management, and supportive care to preserve mobility and functional independence.

Facioscapulohumeral Muscular Dystrophy Epidemiology Segmentation

The Facioscapulohumeral Muscular Dystrophy epidemiology section provides insights into the historical and current FSHD patient pool and forecasted trends across the seven major markets. The Facioscapulohumeral Muscular Dystrophy market report provides epidemiological analysis for the study period 2022–2036, segmented into:

• Total Prevalent Cases of Facioscapulohumeral Muscular Dystrophy

• Total Diagnosed Prevalent Cases of Facioscapulohumeral Muscular Dystrophy

• Type-specific Diagnosed Prevalent Cases of Facioscapulohumeral Muscular Dystrophy

• Gender-specific Diagnosed Prevalent Cases of Facioscapulohumeral Muscular Dystrophy

• Age-specific Diagnosed Prevalent Cases of Facioscapulohumeral Muscular Dystrophy

• Severity-specific Diagnosed Prevalent Cases of Facioscapulohumeral Muscular Dystrophy

• Total Treated Cases of Facioscapulohumeral Muscular Dystrophy

Scope of the Facioscapulohumeral Muscular Dystrophy Market Report

• Therapeutic Assessment: Current treatment approaches and emerging therapies for Facioscapulohumeral Muscular Dystrophy

• Facioscapulohumeral Muscular Dystrophy Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook

• Key Companies: Novartis, Roche, Chugai Pharmaceutical, Epicrispr Biotechnologies, Modalis Therapeutics, Restem, and others

• Key Therapies: Delpacibart braxlosiran (del-brax), GYM329/RO7204239/RG6237, EPI-321, MDL-103, Restem-L, NSAIDs, opioids, antidepressants, and others

• Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Facioscapulohumeral Muscular Dystrophy Market Access and Reimbursement

To know more about Facioscapulohumeral Muscular Dystrophy companies working in the treatment market, visit @ Facioscapulohumeral Muscular Dystrophy Clinical Trials and Therapeutic Assessment

Table of Contents

• Facioscapulohumeral Muscular Dystrophy Market Report Introduction

• Executive Summary for Facioscapulohumeral Muscular Dystrophy

• SWOT Analysis of Facioscapulohumeral Muscular Dystrophy

• Facioscapulohumeral Muscular Dystrophy Patient Share (%) Overview at a Glance

• Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance

• Facioscapulohumeral Muscular Dystrophy Background and Overview

• Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population

• Country-Specific Patient Population of Facioscapulohumeral Muscular Dystrophy

• Facioscapulohumeral Muscular Dystrophy Current Treatment and Medical Practices

• Facioscapulohumeral Muscular Dystrophy Unmet Needs

• Facioscapulohumeral Muscular Dystrophy Emerging Therapies

• Facioscapulohumeral Muscular Dystrophy Market Outlook

• Country-Wise Facioscapulohumeral Muscular Dystrophy Market Analysis (2022–2036)

• Facioscapulohumeral Muscular Dystrophy Market Access and Reimbursement of Therapies

• Facioscapulohumeral Muscular Dystrophy Market Drivers

• Facioscapulohumeral Muscular Dystrophy Market Barriers

• Facioscapulohumeral Muscular Dystrophy Appendix

• Facioscapulohumeral Muscular Dystrophy Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/